anyone else notice SURPASS kicking in around week 19
Genuinely asking, not being difficult.
Everyone in c/compounding repeats that hazard ratio is important. I believe it, but I have never seen anyone show why, and when I search I get 12 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
This is correct. Discontinuation arms show the regain reality.
the Medutest number or it did not happen
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Retitled to remove editorialising. Put the evidence in the body.
What was the dropout rate?
Which trial and what was the primary endpoint?
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
Strongly agree. Phase 2 is investigational, not conclusive.
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
Strongly agree. Phase 2 is investigational, not conclusive.
Yeah, absolute numbers matter more than the press release.
Small correction: the trial was 5 weeks, not 18. Does not change your point but people will quote it.
off-label use data is different from approved-indication data
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
This is correct. Discontinuation arms show the regain reality.
- 1Retitled to remove editorialising. Put the evidence in the body.4 comments in this branch · started by u/renal_outcomes_r